Clinical Scorecard: Prognostic Assessment of Disease Severity in Primary Sclerosing Cholangitis: Validation of Anali Scores and Evaluation Against Functional Stricture Potential

At a Glance

Key Highlights

• Anali scoring system (with and without gadolinium) accurately predicts 4-year radiologic progression and clinical outcomes including liver decompensation, death, and need for liver transplant
• Gadoxetic acid-enhanced MRI (GA-MRI) enables non-invasive diagnosis of potential functional strictures (PFS) that predict advanced PSC stages and adverse outcomes
• Combined evaluation of Anali scores and PFS on GA-MRI improves prognostic stratification in PSC patients

Guideline-Based Recommendations

Diagnosis

• Use T2-weighted magnetic resonance cholangiopancreatography (MRCP) as the imaging modality of choice for PSC diagnosis due to high specificity and accuracy
• Confirm PSC diagnosis according to EASL guidelines, excluding secondary causes and small-duct PSC
• Employ gadoxetic acid-enhanced MRI to assess potential functional strictures and liver function

Management

• Monitor PSC progression and risk stratify patients using validated Anali scores (ANALIGdAP, ANALIGdHBP, ANALINoGd)
• Consider orthotopic liver transplantation (OLT) in patients with advanced disease indicated by imaging and clinical scores
• Exclude unrelated malignancies and manage PSC-associated malignancies appropriately

Monitoring & Follow-up

• Perform serial GA-MRI including T2-weighted MRCP to evaluate disease progression and functional strictures
• Regularly assess clinical scores such as MELD, Revised Mayo Risk Score, Fib-4, APRI, ALBI, UK-PSC risk scores, and PI-AOM for disease severity
• Track clinical events including liver decompensation, OLT, and mortality

Risks

• PSC progression to liver decompensation, liver-related death, and need for transplantation
• Development of clinically relevant strictures requiring ERCP intervention
• PSC-associated malignancies including cholangiocarcinoma, hepatocellular carcinoma, and gallbladder cancer

Patient & Prescribing Data

Adults with large-duct PSC undergoing GA-MRI for disease assessment

Non-invasive imaging with GA-MRI and Anali scoring aids in prognostication and timing of interventions such as liver transplantation; no direct pharmacologic treatment data provided

Clinical Best Practices

• Utilize standardized 3 Tesla GA-MRI protocols including 2D and 3D T2-weighted MRCP sequences for comprehensive PSC evaluation
• Apply validated Anali scores with and without gadolinium contrast to predict disease progression and outcomes
• Incorporate assessment of potential functional strictures (PFS) on GA-MRI to identify patients at risk for advanced disease and adverse events
• Exclude confounding liver diseases and unrelated malignancies to ensure accurate PSC diagnosis and prognosis
• Use combined imaging and clinical scoring systems for optimal risk stratification and management planning

References

• European Association for the Study of the Liver (EASL) Clinical Practice Guidelines
• Ruiz et al. Development of Anali scoring system
• Lemoinne et al. Validation of Anali scores
• Poetter-Lang et al. Gadoxetic acid-enhanced MRI for functional stricture diagnosis
• International PSC Study Group MRCP protocol recommendations